Why do we reject a graff? Role of indirect allorecognition in graft rejection

Kidney International

Volumn 56, Issue 5, 1999, Pages 1967-1979

  Sayegh, Mohamed H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acute rejection; Chronic allograft rejection; Transplant glomerulopathy; Transplant nephropathy

Indexed keywords

ALLOANTIGEN; HLA ANTIGEN CLASS 2;

ADULT; ANTIBODY PRODUCTION; ANTIGEN RECOGNITION; CASE REPORT; CELL MEDIATED CYTOTOXICITY; GRAFT FAILURE; GRAFT REJECTION; HUMAN; IMMUNOGENICITY; IMMUNOREACTIVITY; KIDNEY TRANSPLANTATION; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; ALLOTRANSPLANTATION; ANTIGEN PRESENTING CELL; ARTICLE; CLINICAL OBSERVATION; CLINICAL STUDY; DELAYED HYPERSENSITIVITY; DIAGNOSIS; IMMUNOLOGY; KIDNEY; PATHOLOGY; PHYSIOLOGY;

ADULT; ANTIGEN-PRESENTING CELLS; GRAFT REJECTION; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; HYPERSENSITIVITY, DELAYED; ISOANTIGENS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; TRANSPLANTATION, HOMOLOGOUS;

EID: 0032589969     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.00751.x     Document Type: Article

References (73)

1. 1. DEMETRIS AJ: Pathology of chronic rejection. Graft 1(Suppl 2):6, 1998
2. 2. CARPENTER CB: Long-term failure of renal transplants: Adding insult to injury. Kidney Int 48:S40-S44, 1995
3. 3. PAUL L: Chronic renal transplant loss. Kidney Int 47:1491-1499, 1995
4. 4. MATAS AJ: Chronic allograft dysfunction: Clinical definitions and risk factors. Graft 1(Suppl 2):48-51, 1998
5. 5. MACKENZIE HS, TULLIUS SG, HEEMAN UW, AZUMA H, RENNKE HG, BRENNER BM, TILNEY NL: Nephron supply is a major determinant of long term renal allograft survival in rats. J Clin Invest 94:2148-2152, 1994
6. 6. TULLIUS SG, TILNEY NL: Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation 59:313-318, 1995
7. 7. CECKA JM: The UNOS Scientific Renal Transplant Registry - Ten Years of Kidney Transplants. Los Angeles, UCLA, 1997, pp 1-14
8. 8. REINSMOEN NL, JACKSON A, MCSHERRY C, WIESNER RH, KONDO M, KROM RA, HERTZ MI, BOLMAN RM, MATAS AJ: Organ-specific patterns of donor antigen-specific hyporeactivity and peripheral allogeneic microchimerism in lung, kidney, and liver transplant recipients. Transplantation 60:1546-1554, 1995
9. 9. TULLIUS SG, HANCOCK WW, HEEMAN U, AZUMA H, TILNEY NL: Reversibility of chronic renal allograft rejection: Critical effect of time after transplantation suggests both host immune dependent and independent phases of progressive injury. Transplantation 58:93-99, 1994
10. 10. SAYEGH MH, CARPENTER CB: Tolerance and chronic rejection. Kidney Int 51(Suppl 58):S11-S14, 1997
11. 11. TAKADA M, CHANDRAKER A, NADEAU KC, SAYEGH MH, TILNEY NL: The role of B7 costimulatory pathway in experimental cold ischemia/reperfusion injury. J Clin Invest 100:1199-1203, 1997
12. 12. CHANDRAKER A, TAKADA M, NADEAU KC, PEACH R, TILNEY NL, SAYEGH MH: CD28-b7 blockade in organ dysfunction secondary to cold ischemia/reperfusion injury. Kidney Int 52:1678-1684, 1997
13. 13. KRIEGER NR, DENGPING Y, FATHMAN CG: CD4+ but not CD8+ cells are essential for allorecognition. J Exp Med 184:2013-2018, 1996
14. 14. SAYEGH MH, WATSCHINGER B, CARPENTER CB: Mechanisms of T cell recognition of alloantigen: The role of peptides. Transplantation 57:1295-1302, 1994
15. 15. SHOSKES DA, WOOD KJ: Indirect presentation of MHC antigens in transplantation. Immunol Today 15:32-38, 1994
16. 16. SAYEGH MH, CARPENTER MH: Role of indirect allorecognition in allograft rejection. Int Rev Immunol 13:221-229, 1996
17. 17. CHITILIAN HV, AUCHINCLOSS H: The indirect pathway in graft rejection. Curr Opin Organ Transplant 2:3-7, 1997
18. 18. BENICHOU G, TAM RC, SOARES LRB, FEDOSEYEVA EV: Indirect T-cell allorecognition: Perspectives for peptide-based therapy in transplantation. Immunol Today 18:67-71, 1997
19. 19. SAYEGH MH, TURKA LA: The role of T cell costimulatory activation in transplant rejection. N Engl J Med 338:1813-1821, 1998
20. 20. MAGEE CC, SAYEGH MH: Peptide-mediated immunosuppression. Curr Opin Immunol 9:669-675, 1997
21. 21. CHICZ RM, URBAN RG, LANE WS, GORGA JC, STERN LJ, VIGNALI AA, STROMINGER JL: Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature 358:764-768, 1992
22. 22. CHICZ R, URBAN R, GORGA J, VIGNALI A, LANE W, SROMINGER J: Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 178:27-47, 1993
23. 23. HUNT DF, MICHEL H, DICKINSON TA, SHABANOWITZ J, COX AL, SAKAGUCHI K, APPELLA E, GREY HM, SETTE A: Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science 256:1817-1820, 1992
24. 24. LIU Z, SUN Y, XI Y, MAFFEI A, REED E, HARRIS P, SUCIU-FOCA N: Contribution of direct and indirect recognition pathways to T cell alloreactivity. J Exp Med 177:1643-1650, 1993
25. 25. BRAUN YM, MCCORMACK A, WEBB G, BATCHELOR RJ: Mediation of acute but not chronic rejection of MHC-incompatible rat kidney grafts by alloreactive CD4 T cells activated by the direct pathway of sensitization. Transplantation 55:117-182, 1993
26. 26. MULUK SC, CLERICI M, VIA CS, WEIR MR, KIMMEL PL, SHEARER GM: Correlation of in vitro CD4+ T helper cell function with clinical graft status in immunosuppressed kidney transplant recipients. Transplantation 52:284-291, 1991
27. 27. SCHULIK RD, WEIR MR, MILLER MW, COHEN DJ, BERMAS BL, SHEARER GM: Longitudinal study in vitro CD4+ T helper cell function in recently transplanted renal allograft patients undergoing tapering of their immunosuppressive drugs. Transplantation 56:590-596, 1993
28. 28. SCHULIK RD, MULUK SC, CLERICI M, BERMAS BL, VIA CS, WEIR MR, SHEARER GM: Value of in vitro CD4+ T helper cell function test for predicting long-term loss of human renal allografts. Transplantation 57:480-482, 1993
29. 29. SHERWOOD RA, BRENT L, RAYFIELD LS: Presentation of alloantigens by host cells. Eur J Immunol 16:569-574, 1986
30. 30. DALCHAU R, FANGMANN J, FABRE JW: Allorecognition of isolated, denatured chains of class I and class II major histocompatibility complex molecules: Evidence for an important role for indirect allorecognition in transplantation. Eur J Immunol 22:669-677, 1992
31. 31. SAYEGH MH, KHOURY SK, HANCOCK WW, WEINER HL, CARPENTER CB: Induction of immunity and oral tolerance with polymorphic class II MHC allopeptides in the rat. Proc Natl Acad Sci USA 89:7762-7766, 1992
32. 32. WATSCHINGER B, GALLON L, CARPENTER CB, SAYEGH MH: Mechanisms of allorecognition: Recognition by in vivo primed T-cells of specific major histocompatibility complex polymorphisms presented as peptides by responder antigen-presenting cells. Transplantation 57:572-577, 1994
33. 33. GALLON L, WATSCHINGER B, MURPHY B, AKALIN E, SAYEGH MH, CARPENTER CB: Indirect pathway of allorecognition: The occurrence of self-restricted T cell recognition of allo-MHC peptides early in acute allograft rejection and its inhibition by conventional immunosuppression. Transplantation 59:612-616, 1995
34. 34. BENICHOU G, TAKIZAWA PA, OLSON CA, MCMILLAN M, SERCARZ EE: Donor major histocompatibility complex (MHC) peptides are presented by recipient MHC molecules during graft rejection. J Exp Med 175:305-308, 1992
35. 35. BENICHOU G, FEDOSEYEVA E, OLSON CA, GREYSEN HM, MCMILLAN M, SERCARZ EE: Limited T cell response to donor MHC peptides and the prevention of allograft rejection. J Immunol 153:938-946, 1994
36. 36. FANGMANN J, DALCHAU R, SAWYER GJ, PRIESTLY CA, FABRE JW: T cell recognition of donor major histocompatibility complex class I peptides during allograft rejection. Eur J Immunol 22:1525-1530, 1992
37. 37. BENHAM A, FABRE JW: Fine specificity of peptide determinants for indirect T cell recognition of class I MHC alloantigens, Transplantation 58:1236-1240, 1994
38. 38. SHIRWAN H, LEAMER M, WANG, HK, MAKOWKA L, CRAMER DV: Peptides derived from a-helices of allogeneic class I major histocompatibility complex antigens are potent inducers of CD4+ and CD8+ T cell and B cell responses after cardiac allograft rejection. Transplantation 59:401-410, 1995
39. 39. GHOBRIAL R, HAMASHIMA T, KLOC M, ETKIN L, STANISLAW S, KAHAN B: Membrane bound or soluble truncated RT1.Aa rat class I major histocompatibility antigens induce specific alloimmunity. Transplantation 60:602-610, 1995
40. 40. VELLA JP, VOS L, CARPENTER CB, SAYEGH MH: The role of indirect allorecognition in experimental late acute rejection. Transplantation 64:1823-1824, 1997
41. 41. AUCHINCLOSS HJ, LEE R, SHEA S, MARKOWITZ JS, GRUSBY MJ, GLIMCHER LH: The role of "indirect" recognition in initiating rejection of skin grafts from major histocompatibility complex class II-deficient mice. Proc Natl Acad Sci USA 90:3373-3377, 1993
42. 42. LEE RS, GRUSBY ML, GLIMCHER LH, WINN HJ, AUCHINCLOSS HJ: Indirect recognition by helper cells can induce donor-specific cytotoxic T lymphocytes in vivo. J Exp Med 179:865-872, 1994
43. 43. STEELE DJR, LAUFER TM, SMILEY ST, ANDO Y, GRUSBY MJ, GLIMCHER LH, AUCHINCLOSS HJ: Two levels of help for B cells alloantibody production. J Exp Med 183:699-703, 1996
44. 44. DALLOUL AH, CHMOUZIS E, NGO K, FUNG-LEUNG W-P: Adoptively transferred CD4+ lymphocytes from CD8-/-mice are sufficient to mediate rejection of MHC class II or class I disparate skin grafts. J Immunol 156:4114-4119, 1996
45. 45. FANGMANN J, DALCHAU R, FABRE JW: Rejection of skin allografts by indirect allorecognition of donor class I major histocompatibility complex peptides. J Exp Med 175:1521-1529, 1992
46. 46. BENHAM AM, SAWYER GJ, FABRE JW: Indirect T cell allorecognition of donor antigens contributes to the rejection of vascularized kidney allografts. Transplantation 59:1028-1032, 1995
47. 47. KRENSKY A, WEISS A, CRABTREE G, DAVIS M, PARHAM P: T-lymphocyte-antigen interactions in transplant rejection. N Engl J Med 322:510-517, 1990
48. 48. VELLA JP, MAGEE C, VOS L, RENNKE H, HANCOCK WW, CARPENTER CB, SAYEGH MH: Indirect allorecognition of donor class II MHC peptides induces vascular rejection of cardiac allografts. Transplantation 67:1523-1532, 1999
49. 49. CHEN W, MURPHY B, WAAGA AM, WILLETT TA, RUSSELL ME, KHOURY SJ, SAYEGH MH: Mechanisms of indirect allorecognition in graft rejection: class II MHC allopeptide specific T cell clones transfer delayed type hypersensitivity responses in vivo. Transplantation 62:705-710, 1996
50. 50. WAAGA A, CHANDRAKER A, SPADOFORA-FERREIRA M, IYENGAR A, KHOURY SJ, CARPENTER CB, SAYEGH MH: Mechanisms of indirect allorecognition: Characterization of MHC class II allopeptide-specific T helper clones from animals undergoing acute allograft rejection. Transplantation 65:876-883, 1998
51. 51. DE KOSTER HS, ANDERSON DE, TERMITJELEN A: T cells sensitized to synthetic HLA-DR3 peptide give evidence of continuous presentation of denatured HLA-DR3 molecules. J Exp Med 169:1191-1196, 1989
52. 52. LIU Z, BRAUNSTEIN NS, SUCIU-FOCA N: T cell recognition of allopeptides in context of syngeneic MHC. J Immunol 148:35-40, 1992
53. 53. LIU Z, SUN YK, XI YP, HONG B, HARRIS EP, REED FE, SUCIU-FOCA N: Limited usage of T cell receptor V beta genes by allopeptide-specific T cells. J Immunol 150:3180-3186, 1993
54. 54. LIU Z, COLOVAI AI, TUGULOA S, REED EF, FISHER PE, MANCINI D, ROSE EA, CORTESINI R, MICHLER RE, SUCIU-FOCA N: Indirect recognition of donor HLA peptides in organ allograft rejection. J Clin Invest 98:1150-1157, 1996
55. 55. VELLA JP, FERREIRA M, MURPHY B, ALEXANDER SI, HARMON W, CARPENTER CB, SAYEGH MH: Indirect allorecognition of MHC allopeptides in human renal transplant recipients with chronic graft dysfunction. Transplantation 64:795-800, 1997
56. 56. CIUBOTARIU R, LIU Z, COLOVAI AI, HO E, ITESCU S, RAVALLI S, HARDY MA, CORTESINI R, ROSE EA, SUCIU FN: Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Invest 101:398-405, 1998
57. 57. HORNICK PI, MASON PD, YACOUB MH, ROSE ML, BATCHELOR R, LECHLER RI: Assessment of the contribution that direct allorecogmakes to the progression of chronic cardiac transplant rejecin humans. Circulation 97:1257-1263, 1998
58. 58. RUSSELL ME, RAISANEN-SOKOLOWSKI A, KOGLIN J, GLYSING-JENSEN T: Immunobiology of chronic rejection: Effector pathways that regulate vascular thickening. Graft 1(Suppl 2):7-10, 1998
59. 59. AZUMA H, CHANDRAKER A, NADEAU K, HANCOCK WW, CARPENTER CB, TILNEY NL, SAYEGH MH: Blockade of T cell costimulation prevents development of experimental chronic allograft rejection. Proc Natl Acad Sci USA 93:12439-12444, 1996
60. 60. RUSSELL ME, HANCOCK WW, AKALIN E, WALLACE AF, GLYSING-JENSEN T, WILLETT T, SAYEGH MH: Chronic cardiac rejection in the Lewis to F344 rat model: Blockade of CD28-B7 costimulation CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. J Clin Invest 97:833-838, 1996
61. 61. CHANDRAKER A, RUSSELL ME, GLYSING-JENSEN T, WILLETT TA, SAYEGH MH: T cell costimulatory blockade in experimental chronic cardiac allograft rejection: Effects of cyclosporine and donor antigen. Transplantation 63:1053-1058, 1997
62. 62. GLYSING-JENSEN T, RAISANEN-SOKOLOWSKI A, SAYEGH MH, RUSMH: Chronic blockade of CD28-B7 mediated T cell costimuby CTLA4Ig reduces intimal thickening in MHC class I and II incompatible mouse heart allografts. Transplantation 164:1641-1645, 1997
63. 63. SAYEGH M, ZHENG X-G, MAGEE C, HANCOCK W, TURKA L: Donor antigen is necessary for the prevention of chronic rejection in CTLA4Ig-treated murine cardiac allografts. Transplantation 64:1646-1650, 1997
64. 64. HANCOCK WW, BUELOW R, SAYEGH MH, TURKA LA: Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes. Nat Med 4:1392-1396, 1998
65. 65. CHANDRAKER A, AZUMA H, NADEAU K, CARPENTER CB, TILNEY NL, HANCOCK WW, SAYEGH MH: Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection. J Clin Invest 101:2308-2318, 1998
66. 66. KIRK AD, HARLAN DM, ARMSTRONG NN, DAVIS TA, DONG V, GRAY GS, HONG X, THOMAS D, FECHNER JH, KNECHTLE SJ: CTLA4Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 94:8789-8794, 1997
67. 67. VELLA JP, KNOFLACH A, WAAGA AM, SAYEGH MH: T cell mediated immune responses in chronic rejection: Role of indirect allorecogand costimulation. Graft 1(Suppl 2):11-17, 1998
68. 68. JUDGE TA, Wu Z, ZHENG X-G, SHARPE AH, SAYEGH MH, TURKA LA: The role of CD80, CD86 and CTLA-4 in alloimmune reand the induction of long-term allograft survival. J Immunol 162:1947-1951, 1999
69. + T cell alloactivation. J Exp Med 190:555-566, 1999
70. 70. SAYEGH MH, ZHENG X-G, MAGEE C, HANCOCK WW, TURKA LA: Donor antigen is necessary for the prevention of chronic rejection in CTLA4Ig-treated murine cardiac allograft recipients. Transplantation 64:1646-1650, 1997
71. 71. KERMAN RH: Can we predict chronic rejection? Humoral immune monitoring assays. Graft 1(Suppl 2):66-68, 1998
72. 72. TAKADA M, NADEAU K, HANCOCK WW, MACKENZIE HS, SHAW GD, WAAGA AM, CHANDRAKER A, SAYEGH MH, TILNEY NL: Effects of explosive brain death on cytokine activation of peripheral organs in the rat. Transplantation 65:1533-1542, 1998
73. 73. DENTON MD, MAGEE CC, SAYEGH MH: Immunosuppressive strategies in transplantation. Lancet 353:1083-1091, 1999